We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 1,141

High Court considers inventive step in Australia
  • Spruson & Ferguson
  • Australia
  • June 26 2015

Last month, on 13 and 14 May 2015, the High Court of Australia heard the Appeal in the rosuvastatin case from the Full Federal Court decision


High Court of Australia hears Myriad appeal
  • Spruson & Ferguson
  • Australia
  • June 16 2015

The High Court of Australia today heard the long anticipated appeal from the unanimous decision of a 5-judge bench of the Full Federal Court to allow


Pharmaceutical patentee faces damages claim from Australian government for blocking generic’s entry
  • Fisher Adams Kelly
  • Australia
  • June 16 2015

A series of events has led to the Commonwealth of Australia attempting to recover damages from the bio pharma company, Sanofi-Aventis, to the tune of


High Court to consider if isolated genes are patentable
  • Gilbert + Tobin
  • Australia
  • June 15 2015

The High Court will hear oral argument in the D'Arcy v. Myriad Genetics Inc & Anor appeal on Tuesday, 16 - Wednesday, 17 June 2015 before all 7 High


An expensive lesson in licensing when exclusively performing an act does not make you an exclusive licensee
  • Baldwins
  • Australia, New Zealand
  • June 10 2015

It's generally well understood that in a number of jurisdictions an exclusive licensee can initiate infringement proceedings. However, the recent


High Court date set: to patent or not to patent isolated DNA?
  • Watermark Patent & Trade Marks Attorneys
  • Australia
  • May 29 2015

The date is set. The High Court of Australia will begin proceedings on 16 June 2015 to ultimately decide the patentability of isolated genetic


Australian High Court confirms that late applications for pharmaceutical patent term extensions may be granted in Australia
  • DLA Piper LLP
  • Australia
  • May 6 2015

Pharmaceutical patent term extension regimes are of critical importance to innovators in the pharmaceutical industry, for whom an ability to exploit


A myriad of problems and opportunities a comparison of the patentability of isolated nucleic acid in the United States and Australia
  • DLA Piper LLP
  • Australia, USA
  • May 6 2015

Due to the inherent nature of the technologies that underpin it, the biotechnology industry has faced challenges worldwide in relation to precisely


Could the courts compel prescribers and dispensers of medicines to help big pharma fight generics?
  • Watermark Patent & Trade Marks Attorneys
  • Australia, United Kingdom
  • May 6 2015

A recent UK court ruling broke new ground in ordering an official health body to issue guidelines on prescribing a generic drug. Could the same thing


Costs of patent amendment application not immutable; opponent ordered to pay substantial legal costs
  • Davies Collison Cave
  • Australia
  • May 4 2015

Departing from the near 'immutable rule' that the amending party pay any other party's legal costs of the amendment